You are here

Topiglan Study Fails To Meet Primary Endpoint

LEXINGTON, Mass., April 14 /PRNewswire/ -- MacroChem Corporation (NASDAQ: MCHM) announced today that preliminary data from its Phase 2 pharmacodynamic study of Topiglan(R), a topical cream for erectile dysfunction, demonstrate that Topiglan did not meet the study's primary clinical endpoints. The randomized, double-blind clinical study, which utilized the RigiScan(R) monitoring technique, compared the efficacy of Topiglan in men with mild-to- moderate erectile dysfunction to a placebo cream.

"While we are disappointed by these preliminary Topiglan data, we continue to advance our clinical studies of EcoNail(TM) and Opterone(TM)," said Robert J. DeLuccia, chief executive officer of MacroChem. "We plan in the weeks ahead to further analyze all of the Topiglan study data."

MacroChem currently has two other clinical programs underway. A dose- proportionality study of Opterone cream, an absorption-enhanced topical treatment for male testosterone deficiency, is ongoing. Patients are currently being dosed and results from that study are expected later this year. The Company has also initiated a Phase 1 study of EcoNail in patients with onychomycosis, a fungal infection of nails. Patient screening is nearly complete and data from this study are expected to be available by the end of the year.

Source: Macrochem

More Headlines

Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Policy Could Be Life-Changing for People With Spinal Cord Injury
Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
Diabetes and Cancer Patients Could Soon Avoid Injections
Early Cancer Development May Begin in Just 30 Minutes
In Most Cases, Plaque/Tangle Dissolution Occurred Almost Instantly